Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TMT + Autologous Stem Cell Transplant in Recurrent Platinum Resistant Ovarian Cancer
NCT00003297Phase 2Completed
- Sponsor
- Georgetown University
- Start
- Dec 1997
- Primary completion
- Jan 2001
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of topotecan in ovarian cancer, sponsored by Georgetown University. Primary endpoints: Maximum Tolerated Dose, Dose Limiting Toxicities and 2 more. Started Dec 1997; status: completed.
02
Drugs
topotecan
03
Conditions
ovarian cancer
Beyond the preview
Go deeper on NCT00003297.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00003297.